Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No, it is out of date...if you click "last" it takes you to 2008-2011 posts. You can also filter by year at top and confirm nothing added to this website section since April 2019. It seems to be a useless section of website they can eliminate... the FAQ and Press Release sections are kept up to date fine. It's access by scrolling to bottom of investors page and clicking "DOWNLOADS" link in center.
As you acknowledge it's been posted elsewhere (just noting I found another link, not sure it's the same source), just adding your question is a very good one:
Does anyone know if Dr. Reddy's has ever made a purchase? If they haven't and do begin to purchase, how will that effect Hikma?
Your link isn't pulling up any article for me, but this link with similar title points to March 16 Financial Express story by Jefferies ... same article perhaps? Article is recommending Dr. Reddy's Labs as Buy, but looks more bullish for AMRN.
Supply chain constraints indicate that Vascepa will remain a limited competition product in the foreseeable future, even after the entry of Hikma and Dr. Reddy’s.
Pharma Customer Engagement Europe tomorrow (500 attendees)
I recall this was already posted, but Amarin's newly named CEO/President KM is speaking here in just over 6 hours (10 am Central European Time = 6 am Eastern Daylight Time). Anyone going or have access?
Also the very first item on agenda of Day 1 (good visibility for Amarin):
From the ground-up. How Amarin Corp built its EU commercial organization with a data-and-digital-focus to deliver in a crowded market
• The vision. How Amarin Corp identified its key principles for a 21st century commercial pharma organization that adds-value with each customer touchpoint
•Hear how Amarin Corp developed it’s Go-To-Market approach with fully comprehensive digital-customer experience, whilst also ensuring they are equipped for field activities when available
•Why you need to create a dynamic model that can transform as data and digital capabilities evolve
Amarin Corporation - Logo Karim Mikhail SVP and Commercial Head, Europe Amarin Corporation
Right now I think LBL has it right: "It's GIA until it isn't." LBL stated in his last posting here that he still expects a BO...just doesn't know when or at what price.
I think AMRN is right to continue to play their cards showing intent to GIA, with the hiring this new CEO with the best experience to succeed at GIA in EU. They need time for share price to recover higher to get a higher BO price to maximize shareholder value. I have confidence that they are laser focused on maximizing shareholder value, and intend to hold my shares regardless of near term market gyrations.
Looking recently to learn more about the BOD, I found this bio of Amarin's chairman of the board, Lars Ekman, very interesting... in his main position for Sofinnova Investments, the goal is clearly nurturing and launching successful drug companies until they "graduate." I have no doubt he's working to move Amarin from the list of "Active Companies" to the list of "Alumni Companies" on his bio page. His last "graduate", Spark Therapeutics, a gene therapy company, was sold to Roche for $4.8B in 2019.
Spark's chart (symbol ONCE) looked similar to AMRN... GIA until it's not, dropping from peak of $92.39 on July 1, 2018 to $34.70 on Dec. 24, 2018, clawing it's way back to $51.56 on Feb. 22, 2019, popping the next trading day to $113.48 on Feb. 25, 2019 on the day the acquisition agreement at $114.50/share was announced here.
Respectful yet strong reply. Thank you again, from a relative newcomer on iHub but longtime AMRN shareholder since just before Reduce-it spike but considerably in the hole nonetheless, for your tireless efforts to restore lost value to so many suffering investors who believe in the science, potential and validity of the patent protection for icosapent ethyl. May Judge Du be open to seeing the truth and correcting the error.
Thank you, Hikma attorney, for this link to remind us why we are disgruntled. The primary dictionary definition of "disgruntled" shows that it is not primarily a negative, pejorative term:
disgruntled [ dis-gruhn-tld ] adjective displeased and discontented; sulky; peevish: Her disgruntled husband refused to join us.
The secondary definition is sometimes co-opted to reflect poorly on those disgruntled, but the primary one invites one to ask "why" are they displeased and discontented. Thank you for providing the link to remind us of Judge Du's inappropriately describing the unique, patented chemical molecule contained in Vascepa as "Fish Oil," revealing either a predisposed bias or lack of understanding of the science.
Those of us who carefully did our due diligence understanding the science behind Vascepa (now approved and protected for 10+ years for distribution in Europe) have very good reason to be quite a bit displeased and discontented that the incorrect court case ruling just over a year ago caused many of us to lose thousands of dollars which we want rightfully restored to us. We now see the truth clearly, due to the hard work of other investors, that this patent decision was based on error and possibly fraud. Who is now pointing in the other direction and saying "look over there" and why?
I was not part of the crowdfunding, but have learned a great deal from reading the intelligent, well-reasoned, sound arguments in the Rule 60 filing, not to mention those in the Supreme Court writ of certiorari amicus briefs. As a careful, Ph.D. educated engineer, I take offense at your characterization of those who are working hard to reveal and promote what is really the truth in this unfortunate saga. Marjac is one of the most articulate, level-headed, intelligent and trustworthy individuals of those I've read. You sir, Hikma attorney, are not.
Global M&A sets first-quarter record as dealmakers shape post-COVID world
MARCH 31, 2021 5:08 PM BOSTON/LONDON (Reuters) - Mergers and acquisitions (M&A) activity surged globally in the first quarter of 2021 to a year-to-date record, as companies and investment firms rushed to get ahead of changes in how people work, shop, trade and receive healthcare during the COVID-19 pandemic. ... “This is as robust and broad-based an M&A market as I have witnessed in the last 20 years,” said Colin Ryan, co-head of Americas M&A at Goldman Sachs Group Inc. “We are in an environment where assets are scarcer than the available capital right now.”
Legally, it was a mistake by Judge Du to invalidate the patents on grounds of prima facie obviousness in reliance upon Mori and Kurabayashi, thereby justifying relief pursuant to Rule 60(b)(1).
In terms of the Hikma legal team, it may be much more than a mistake. Misrepresentation to be exact, thereby justifying relief pursuant to Rule 60(b)(3).
Searching for more background on Judge Du, found this (excuse me if it's been previously shared here):
In addition to serving as chief judge, she also serves as one of three judges participating in the Patent Pilot Program, whereby patent cases are assigned to the judges if the presiding judge elects to reassign the case. Du enjoys her work on patent cases; she said, “I get to be tutored on varied technical issues involved in patent cases, such as learning how tasers work or the benefits of fish oil.”
She also enjoys watching experienced attorneys at work. “I am most impressed when attorneys are thoroughly prepared, know the issues to highlight, know when to concede unavailing points while moving on to the next best arguments, and demonstrate professionalism and respect for opposing counsel,” she said. “Periodically, I see a performance from experienced attorneys that combines all these qualities like a symphony, and I am reminded of how much I enjoy what I get to do.” Du has the following advice for attorneys – not just those appearing before her. “Be diligent and always consider your audience. Maintain your integrity and guard your reputation,” she said...
Approach Judge Du with respect, be well prepared, and know she highly values integrity and reputation. Also, being new to patent law, she may be open to correcting the error highlighted in the Rule 60 filing. Fingers crossed.
Even though I own a significant amount of this stock I've only been a reader of this board. There are so many REALLY knowledgeable posters here!!!! I do extend huge thanks to all of the many experts here, you all know who you are. This is an exceptional message board.
I would like to offer many thanks to all the lawyers and scientists and technical experts and investment guru's that post here, it really is outstanding following this board!!!
Thank you!!!
DITTO... this board is very helpful for understanding the AMRN saga clearly and from multiple perspectives. Thank you all!